@article{oai:tohoku-mpu.repo.nii.ac.jp:00000741,
 author = {渡辺, 夏美 and Watanabe, Natsumi and 佐藤, 伸輔 and Satoh, Shinsuke and 櫻井, 淳二 and Sakurai, Junji and 石澤, 文章 and Ishizawa, Fumiaki and 宮坂, 智充 and Miyasaka, Tomomitsu and 河野, 資 and Kawano, Tasuku and 大河原, 雄一 and Ohkawara, Yuichi and 小嶋, 文良 and Ojima, Fumiyoshi and 高橋, 知子 and Takahashi, Tomoko},
 issue = {64},
 journal = {東北医科薬科大学研究誌, Journal of Tohoku Medical and Pharmaceutical University},
 month = {Dec},
 note = {We report a case in which Neoral® capsules were used to treat a patient with steroid-resistant nephrotic syndrome complicated with membranous proliferative glomerulonephritis. In this case, referring to the latest guidelines, a dosage regimen different from that included in the package insert for Neoral® capsules was used. Furthermore, the blood concentration of cyclosporine was not measured at conventional trough levels, but at an index for to avoid side effects by measuring the blood concentration 2 hours after taking cyclosporine（C2 value）, which was the maximum blood concentration. Pharmacists should refer not only to the dosage regimen described in the package insert, but also to the latest guidelines for optimal medication to reduce the possibility of side effects.},
 pages = {109--114},
 title = {膜性増殖性糸球体腎炎に合併したステロイド抵抗性ネフローゼ症候群に対するネオーラル®カプセル併用が著効した一例 ── 薬剤師として介入すべき点──},
 year = {2017},
 yomi = {ワタナベ, ナツミ and サトウ, シンスケ and サクライ, ジュンジ and イシザワ, フミアキ and ミヤサカ, トモミツ and カワノ, タスク and オオカワラ, ユウイチ and オジマ, フミヨシ and タカハシ, トモコ}
}